We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts forecast that Danaher (DHR - Free Report) will report quarterly earnings of $1.84 per share in its upcoming release, pointing to a year-over-year increase of 2.2%. It is anticipated that revenues will amount to $6.09 billion, exhibiting an increase of 2.6% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Danaher metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Total Sales- Diagnostics' will reach $2.33 billion. The estimate points to a change of +0.8% from the year-ago quarter.
According to the collective judgment of analysts, 'Total Sales- Life Sciences' should come in at $1.79 billion. The estimate indicates a year-over-year change of +0.9%.
The average prediction of analysts places 'Total Sales- Biotechnology' at $1.95 billion. The estimate indicates a change of +5.5% from the prior-year quarter.
The consensus among analysts is that 'Operating profit- Biotechnology' will reach $574.60 million. Compared to the present estimate, the company reported $531.00 million in the same quarter last year.
The consensus estimate for 'Operating profit- Diagnostics' stands at $521.81 million. Compared to the current estimate, the company reported $554.00 million in the same quarter of the previous year.
Danaher shares have witnessed a change of +13% in the past month, in contrast to the Zacks S&P 500 composite's +0.5% move. With a Zacks Rank #2 (Buy), DHR is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts forecast that Danaher (DHR - Free Report) will report quarterly earnings of $1.84 per share in its upcoming release, pointing to a year-over-year increase of 2.2%. It is anticipated that revenues will amount to $6.09 billion, exhibiting an increase of 2.6% compared to the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Danaher metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Total Sales- Diagnostics' will reach $2.33 billion. The estimate points to a change of +0.8% from the year-ago quarter.
According to the collective judgment of analysts, 'Total Sales- Life Sciences' should come in at $1.79 billion. The estimate indicates a year-over-year change of +0.9%.
The average prediction of analysts places 'Total Sales- Biotechnology' at $1.95 billion. The estimate indicates a change of +5.5% from the prior-year quarter.
The consensus among analysts is that 'Operating profit- Biotechnology' will reach $574.60 million. Compared to the present estimate, the company reported $531.00 million in the same quarter last year.
The consensus estimate for 'Operating profit- Diagnostics' stands at $521.81 million. Compared to the current estimate, the company reported $554.00 million in the same quarter of the previous year.
View all Key Company Metrics for Danaher here>>>Danaher shares have witnessed a change of +13% in the past month, in contrast to the Zacks S&P 500 composite's +0.5% move. With a Zacks Rank #2 (Buy), DHR is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .